Inhibrx Inc. (INBX) News
Filter INBX News Items
INBX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest INBX News From Around the Web
Below are the latest news stories about INHIBRX INC that investors may wish to consider to help them evaluate INBX as an investment opportunity.
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsInhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the third quarter of 2023 and provided an update on recent corporate highlights. |
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide (IRI/TMZ) for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Inhibrx presented this dataset as of the data cut of September 8th, 2023 at the Annual Connective Tissue Oncology Society (CTOS) C |
Inhibrx Announces Participation in Upcoming Scientific ConferencesInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming scientific conferences: |
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmaceutici S.p.A ("Chiesi") declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD"). |
12 Best High Risk High Reward Stocks To Buy NowIn this piece, we will take a look at the 12 best high risk high reward stocks to buy now. If you want to skip our background on investing, then head on over to 5 Best High Risk High Reward Stocks To Buy Now. Investing is a risky endeavor, as is anything that involves the […] |
Inhibrx Announces $200 Million Private Placement FinancingInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the "PIPE") that is expected to result in gross proceeds of approximately $200 million. The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Manage |
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsInhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2023 and provided an update on recent corporate highlights. |
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin DeficiencyInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for the treatment of patients with emphysema due to alpha-1 antitrypsin deficiency (AATD). |
Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue EstimatesInhibrx, Inc. (INBX) delivered earnings and revenue surprises of -33.33% and 94.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsInhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2023 and provided an update on recent corporate highlights. |